Background Recently, an angiotensin-converting enzyme inhibitor was shown to have a beneficial effect on virusinduced myocardial injury. We investigated the effect of a new angiotensin II type 1 receptor antagonist, (+)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate , in an animal model of viral myocarditis induced by encephalomyocarditis virus.
Methods and Results Four-week-old DBA/2 mice were inoculated with the encephalomyocarditis virus. TCV-116 (in 5% gum arabic) was given 1 day before (1 or 10 mg/kg) or 2 days after virus inoculation (0.3 or 3 mg/kg). Control mice received the vehicle only. All drugs were administered orally on a daily basis, and the animals were killed on day 14. When treatment was started 1 day before inoculation, the survival of mice receiving 10 mg/kg of TCV-116 improved (17 of 20 [85%] T nhe renin-angiotensin system is one of the most important factors in the pathophysiology of cardiovascular diseases such as hypertension and congestive heart failure. Many drugs that modify the activity of this system have been developed, and angiotensin-converting enzyme (ACE) inhibitors such as captopril have been reported to be beneficial in patients with congestive heart failure. [1] [2] [3] [4] Dilated cardiomyopathy (DCM) is a heart muscle disease of unknown origin that progresses to severe heart failure and can only be treated with heart transplantation in the terminal stage. Many etiological factors have been proposed, although viral 
Experiment 3
To determine the plasma angiotensin II level in infected and noninfected mice, 15 four-week-old mice were inoculated with the virus, and whole-body blood was obtained from the orbital venous plexus on day 5 (n=5), day 7 (n=4), or day 14 (n=6). Blood was also obtained from noninfected mice (n=5). Blood was mixed with Trasirol/EDTA and centrifuged to separate the plasma, which was stored at -70°C. The 
Histological Examination
The hearts were fixed in 10% formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The extent of myocardial calcification, necrosis, and cellular infiltration was blindly graded by two observers and was scored as follows: 0, no lesions; 1+, lesions involving <25% of the myocardium; 2+, lesions involving 25% to 50% of the myocardium; 3+, lesions involving 50% to 75% of the myocardium; and 4+, lesions involving 75% to 100% of the myocardium. The scores assigned by the two observers were averaged.
Myocardial Viral Titer
For the assay of viral replication, hearts were ground with autoclaved sea sand in EMEM. After centrifugation, 0.1 mL of the supernatant was inoculated onto human amniotic cell monolayers for the plaque-forming assay. The viral titer was expressed as logl pfu/mg heart.
Statistical Analysis
Survival was analyzed by the Kaplan-Meier method. Statistical analysis of data on body weight, heart weight, histological score, myocardial virus concentration, and plasma angiotensin II concentration was performed by one-way ANOVA.
Results
Experiment 1-Effect of TCV-116 on Survival, Body and Heart Weight, and Myocardial Histology Survival When TCV-116 treatment was started 1 day before virus inoculation, 13 of 20 mice (65%) given 1 mg/kg survived, as did 17 of 20 mice (85%) given 10 mg/kg. Survival was better than in the vehicle control group (14 of 22 mice, 64%), but the difference was not significant (Table) . The Body and Heart Weight Although body weight was similar in each group, heart weight was significantly lower in the mice given TCV-116 at 3 mg/kg per day (106±24 mg, P<.05) than in the control group (133±33 mg) (Fig 2) .
Myocardial Histology
The histological score for myocardial necrosis was 2.3±+1.2 in the control group, 1.9±0.7 in mice given TCV-116 at 0.3 mg/kg, and 1.1±0.3 in mice treated at 3 mg/kg. The respective scores for cellular infiltration were 2.6±1.3, 2.1±0.5, and 1.4+0.7, and the respective scores for calcification were 2.1 1.1, 1.9±0.7, and 1.1±0.3. In mice given TCV-116 at 3 mg/kg per day, all scores were significantly lower than in the control group (Fig 3) . Representative histological findings are shown in On day 5 after viral inoculation, the viral titer was 3.1±0.8 log10 pfu/mg in the control group and 2.8±0.6 log10 pfu/mg in the TCV-116-treated group. There was no significant difference between the two groups. Experiment 3 -Plasma Angiotensin II Levels
The plasma angiotensin II level in infected mice was 43.0±12.4 pg/mL on day 5, 51.3±13.4 pg/mL on day 7, 
Discussion
Various types of heart disease cause congestive heart failure. Among them, viral myocarditis is one of the most important causes of DCM.9-15 The goals of therapy in patients with DCM are to improve cardiac function and to inhibit the progression of myocardial necrosis 
